Liver Cancer | Topics

 
Ghassan K. Abou-Alfa, MD, Discusses Next Steps in Researching Unresectable HCC
November 23, 2022

Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.

Ghassan K. Abou-Alfa, MD, Spotlights Patients With Unresectable HCC Who May Best Benefit From Tremelimumab/Durvalumab
November 12, 2022

Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.

PTCV Plus pIL-12 and Pembrolizumab Demonstrates Promising Responses in Unresectable/Metastatic HCC
November 08, 2022

A regimen consisting of personalized therapeutic cancer vaccine, GNOS-PV02, as well as plasmid-encoded IL-12 and pembrolizumab yielded an overall response rate of 20.9% among evaluable patients with unresectable or metastatic hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, Discusses Importance of Treatment Accessibility in Unresectable HCC
November 06, 2022

Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.

OTX-2002 Receives Orphan Drug Designation From the FDA for HCC
November 02, 2022

Patients with hepatocellular carcinoma may benefit from treatment with OTX-2002, a first-in-class epigenomic controller designed to downregulate c-Myc that recently received orphan drug designation from the FDA

Ghassan K. Abou-Alfa, MD, Highlights Approval of Tremelimumab and Durvalumab in Unresectable HCC
October 31, 2022

Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.

Sorafenib Plus SBRT Yields Improved Survival Vs Sorafenib Alone in Locally Advanced HCC
October 25, 2022

Stereotactic body radiation therapy is a new standard of care option for patients with locally advanced hepatocellular carcinoma, according to a presentation on the phase 3 NRG/RTOG 1112 trial assessing sorafenib combined with stereotactic body radiation therapy.

FDA Approves Tremelimumab Plus Durvalumab in Unresectable HCC
October 24, 2022

Based on results from the phase 3 HIMALAYA trial, the FDA has approved tremelimumab plus durvalumab in patients with unresectable hepatocellular carcinoma.

FDA Grants Orphan Drug Designation to ET140203 T Cells for Hepatoblastoma
October 19, 2022

The FDA has given orphan drug designation to ET140203 ARTEMIS, an investigational therapy for hepatoblastoma, the safety and potential efficacy of which are being evaluated in the phase 1/2 ARYA-1 and ARYA-2 studies.

FDA Grants Accelerated Approval to Futibatinib in FGFR2+ Locally Advanced/Metastatic Intrahepatic Cholangiocarcinoma
September 30, 2022

Results from the phase 1/2 TAS-120-101 trial lead to the accelerated approval of futibatinib in patients with locally advanced or metastatic cholangiocarcinoma and an FGFR2 gene fusion or rearrangement.